We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Laura Elizabeth Lansdowne

Senior Science Writer

Contact Us

Writes for:

Drug Discovery Cancer Research

Latest Content From Laura Elizabeth Lansdowne

Testing a Drug Compound in Clinical Trials
Article

In a recent interview with Technology Networks, Dr Stephen Wright, Independent Consultant in medicines development, talks us through the various stages of clinical drug development. He explains what is meant by an IND application, discusses how clinical trials are designed and how the data generated in these trials is processed.

VIEW

The Genetics of Cancer
Infographic

Cancer is the term used to describe an incredibly complex group of diseases, caused by changes to the genes in one cell or a group of cells. In this infographic we explore the genetics of cancer, the The predictive and diagnostic power of genetic-based tools, and much more.

VIEW

Identifying and Optimizing a Promising Drug
Article

In a recent interview with Technology Networks, Prof. Paul Brennan from the University of Oxford explains that proteins “make up approximately 60% of what is in a cell.” So, it is no surprise that almost all approved drugs act by targeting these complex macromolecules.

VIEW

How Are Drugs Developed?
Article

You are unwell, you see a doctor, and in some instances the doctor writes a prescription for a drug that is designed to help with your condition. But how exactly is that drug developed and how long did it take for the “final product”, that now sits neatly on the pharmacy shelf, to become available to patients?

VIEW

Developing Drugs for Difficult-to-treat Diseases
Industry Insight

Technology Networks recently spoke with Mike Sherman, Chief Executive Officer at Chimerix to learn more about the company’s oncology, biodefense and COVID-19 therapeutic efforts.

VIEW

Tracking Global COVID-19 Clinical Trials
Industry Insight

In efforts to find efficacious interventions against SARS-CoV-2, the novel coronavirus that causes COVID-19, hundreds of clinical trials have been designed and launched at an unprecedented rate across the globe. As data emerges from these studies there is an urgent need to track progress, to ensure transparent communication of findings, and to avoid duplication of efforts. Technology Networks spoke with Cytel’s Edward Mills, Vice President of Real-World Evidence and Senior Principal Scientist, to learn more about the global COVID-19 Trial Tracker the company has recently launched.

VIEW

The Evolution of Cancer Drug Discovery
Infographic

For many years, the only available treatment option for cancer patients was removal or cauterization of cancerous tissue. Since then, numerous additional therapeutic strategies have been developed. This infographic explores the evolution of cancer drug discovery.

VIEW

Identifying and Addressing Bias in Drug Development: An Interview With Dr Namandje N. Bumpus
Article

In this interview with Technology Networks, Namandje N. Bumpus, Ph.D, Associate Dean for Basic Research and Associate Professor of Medicine from Johns Hopkins discusses the presence of bias from bench to bedside, highlights how this can impact clinical success, and explores ways to address bias throughout the drug development process.

VIEW

Exploring Differences in Drug Response With Dr Namandje N. Bumpus
Article

For the same dose of the same drug, two individuals might experience very different effects. This variation in drug response can be impacted by several drug-specific, genetic, biological, and environmental factors, and the interplay between these factors. In this interview, Namandje N. Bumpus, Ph.D, Associate Dean for Basic Research and Associate Professor of Medicine, from Johns Hopkins, elaborates on her work exploring the differences between people in relation to drug response.

VIEW

Ensuring High-quality Cancer Care During the COVID-19 Pandemic
Industry Insight

Technology Networks recently had the pleasure of speaking to Dr Sandeep “Bobby” Reddy, Chief Medical Officer of NantHealth to gain a better understanding of the impact COVID-19 is having on the treatment of cancer. Reddy discusses what is currently known, in terms of risk and severity of SARS-CoV-2 infection in individuals with cancer, and elaborates on the innovative approaches that have been adopted by oncologists to enable continuation of high-quality care during the pandemic.

VIEW